Combining immunotherapy with chemotherapy shows promise in enhancing survival rates for extensive-stage small cell lung ...

It had been hoped that RA patients might actually benefit more from these drugs, known as immune checkpoint inhibitors (ICIs) ...

Boehringer Ingelheim unveiled new data from its top oncology prospect zongertinib, further backing the drug’s prowess in ...

A real-world study from India demonstrated that ultralow-dose nivolumab (40 mg every 2 weeks) combined with chemotherapy showed promising results in non–small cell lung cancer (NSCLC).

Boehringer Ingelheim’s drug candidate for human epidermal growth factor receptor 2 (HER2)-mutated non-small cell lung cancer ...

While there have been massive strides forward in treating cancer in the last decades – with a doubling in survival rates in the last ... and an ongoing lung cancer screening drive rolled out ...

In the Chinese mainland, toripalimab was the first domestic anti-PD-1 monoclonal antibody approved for marketing (approved in China as TUOYI ® ). Currently, there are twelve approved indications for ...

The FDA has started a priority review of Amgen’s tarlatamab for small cell lung cancer (SCLC ... with this form of cancer typically have a five-year survival rate of just 7%, with few treatment ...

Cancer patients invariably develop resistance to targeted drugs, so drugmakers develop strategies to combat it before ...

Topline data were announced from a phase 3 trial evaluating tarlatamab for the treatment of SCLC in patients who progressed on or after a single line of platinum-based chemotherapy.